Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $169
Johnson & Johnson Pivots Its AI Strategy -- WSJ
Johnson & Johnson Options Spot-On: On April 17th, 82,557 Contracts Were Traded, With 535.06K Open Interest
UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com
$JNJ Stock Is up 2% Today. Here's What We See in Our Data.
Johnson & Johnson Is Maintained at Equal-Weight by Barclays
Least Shorted S&P 500 Stocks in March
Short Bets Against S&P 500 Healthcare Stock Rises in March; MRNA Stays Top Shorted
Express News | Johnson & Johnson : Barclays Cuts Target Price to $165 From $166
Addex Reclaims Rights to Epilepsy Drug as Janssen Ends Partnership
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $169
New Analyst Forecast: $JNJ Given 'Outperform' Rating
Tariff clouds loom heavy! Barclays names the U.S. stock medical instruments Industry as the 'pressure-resistant king' and the 'hard-hit area'.
Barclays issued a research report analyzing the impact of the new tariff policy of the Trump administration on the medical instruments industry.
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
UBS Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $180
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Johnson & Johnson Price Target Raised to $164.00/Share From $162.00 by Raymond James
Johnson & Johnson Is Maintained at Outperform by Raymond James